ANL (Adlai Nortye) Total Liabilities: $42.76 Mil (As of Dec. 2025)


What is Adlai Nortye Total Liabilities?

Adlai Nortye ANL -10.47% Total Liabilities is $42.76 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Adlai Nortye's Total Liabilities for the quarter that ended in Dec. 2025 was $42.76 Mil.

Adlai Nortye's quarterly Total Liabilities increased from Dec. 2024 ($45.79 Mil) to Jun. 2025 ($64.12 Mil) but then declined from Jun. 2025 ($64.12 Mil) to Dec. 2025 ($42.76 Mil).

Adlai Nortye's annual Total Liabilities declined from Dec. 2023 ($55.14 Mil) to Dec. 2024 ($45.79 Mil) and declined from Dec. 2024 ($45.79 Mil) to Dec. 2025 ($42.76 Mil).

Adlai Nortye Total Liabilities Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye Total Liabilities Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
317.11 313.89 55.14 45.79 42.76

Adlai Nortye Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only 55.14 54.31 45.79 64.12 42.76

Adlai Nortye Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Adlai Nortye's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=41.628+(1.127+2.4424906541753E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=42.76

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=34.433--8.322
=42.76

Adlai Nortye's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=41.628+(1.127+2.4424906541753E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=42.76

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=34.433--8.322
=42.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $42.76 Mil mean?
Adlai Nortye (ANL) has a Total Liabilities of $42.76 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Adlai Nortye and its competitors.
Is Adlai Nortye's Total Liabilities too high?
Adlai Nortye's current Total Liabilities is $42.76 Mil.
How does Adlai Nortye's Total Liabilities compare to OMER and PRME?
Adlai Nortye's Total Liabilities of $42.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Adlai Nortye and its competitors. Adlai Nortye's current Total Liabilities is $42.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Total Liabilities of $42.76 Mil. The current Total Liabilities is $42.76 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Total Liabilities is $42.76 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.